Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, such as octreotide, is a promising option for the treatment of somatostatin-receptor-positive endocrine tumors. Here, van Essen et al. evaluate data from preliminary studies of PRRT, and discuss the pros and cons of this approach. The authors propose that PRRT might soon become the treatment of choice for patients with metastatic or inoperable endocrine tumors.
- Martijn van Essen
- Eric P. Krenning
- Dik J. Kwekkeboom